Tolero Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Tolero Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013490
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:34
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Tolero Pharmaceuticals Inc (Tolero), a subsidiary of Dainippon Sumitomo Pharma America Holdings Inc, is a drug company that offers medicines to treat cancer and other serious human diseases. The company’s alvocidib is a cyclin dependent kinase inhibitor with selective activity against CDK9 and also CDK4/6. Tolero’s alvocidib is also indicated for various types of cancer including solid tumors and hematological malignancies. The company’s preclinical stage products include TP-1287, TP-0903 and TP-0184. Its inhibitors provide treatment for diseases that accumulate abnormalities in cell functions such as mutation, amplification, deletion, and others. Tolero is headquartered in Lehi, Utah, the US.

Tolero Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Tolero Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Tolero Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Tolero Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Tolero Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Tolero Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 9
Tolero Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Tolero Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Tolero Pharma Acquires Drug Development Assets From Astex Pharma 11
Venture Financing 13
Tolero Pharma Raises USD8.2 Million in Second Tranche of Series B Financing 13
Tolero Pharma Raises USD14.2 Million in Series B Venture Financing 14
Tolero Pharma Raises US$3.33 Million In Venture Financing 15
Partnerships 16
Eutropics Enters Into Co-Development Agreement With Tolero Pharma 16
Licensing Agreements 17
Tolero Pharma Enters Into Licensing Agreement With Sanofi For Alvocidib 17
MannKind Enters Into Licensing Agreement With Tolero Pharma For Bruton’s Tyrosine Kinase Inhibitors 18
Acquisition 19
Sumitomo Dainippon Pharma Acquires Tolero Pharma 19
Tolero Pharmaceuticals Inc – Key Competitors 21
Tolero Pharmaceuticals Inc – Key Employees 22
Tolero Pharmaceuticals Inc – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Product News 24
11/15/2016: Tolero Pharmaceuticals to Present Progress of Leukemia Program at the 58th ASH Annual Meeting and Exposition 24
06/13/2016: Tolero Pharmaceuticals Presents Nonclinical Data Demonstrating Alvocidib Provides Drug Combination Strategies Due to the Targeting of MCL-1 25
06/06/2016: Tolero Pharmaceuticals To Present Update On Alvocidib Program At 2016 EHA Congress 26
06/06/2016: Tolero Pharmaceuticals To Present Update On TP-1287 Program At 2016 EHA Congress 27
04/20/2016: Tolero Pharmaceuticals Presents Nonclinical Data Demonstrating Alvocidib Provides Multiple Drug Combination Strategies Due to the Targeting of MCL-1 28
Clinical Trials 29
Nov 15, 2016: Tolero Pharmaceuticals to Present Progress of Anemia Program at the 58th ASH Annual Meeting and Exposition 29
Apr 18, 2016: Tolero Pharmaceuticals Presents Data Demonstrating AXL Inhibition Leads to a Reversal of a Mesenchymal Phenotype Sensitizing Cancer Cells to Targeted Agents and Immuno-Oncology Therapies 30
Apr 12, 2016: Tolero Pharmaceuticals to Present Update on Alvocidib at the AACR Annual Meeting 2016 31
Apr 12, 2016: Tolero Pharmaceuticals to Present Update on TP-0903 at the AACR Annual Meeting 2016 32
Mar 08, 2016: Tolero Pharmaceuticals to Present at the 13th Annual BIO Asia International Conference 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
Tolero Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Tolero Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Tolero Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Tolero Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Tolero Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Tolero Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 9
Tolero Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Tolero Pharma Acquires Drug Development Assets From Astex Pharma 11
Tolero Pharma Raises USD8.2 Million in Second Tranche of Series B Financing 13
Tolero Pharma Raises USD14.2 Million in Series B Venture Financing 14
Tolero Pharma Raises US$3.33 Million In Venture Financing 15
Eutropics Enters Into Co-Development Agreement With Tolero Pharma 16
Tolero Pharma Enters Into Licensing Agreement With Sanofi For Alvocidib 17
MannKind Enters Into Licensing Agreement With Tolero Pharma For Bruton’s Tyrosine Kinase Inhibitors 18
Sumitomo Dainippon Pharma Acquires Tolero Pharma 19
Tolero Pharmaceuticals Inc, Key Competitors 21
Tolero Pharmaceuticals Inc, Key Employees 22

★海外企業調査レポート[Tolero Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kobayashi Pharmaceutical Co Ltd (4967)-医療機器分野:企業M&A・提携分析
    Summary Kobayashi Pharmaceutical Co Ltd (Kobayashi) is a manufacturer and distributor of pharmaceutical, health and personal care products. The company offers OTC pharmaceuticals, oral hygiene products, deodorizing air fresheners, cooling gel sheets, sanitary products, household sundries, and body w …
  • Salvatore Ferragamo SpA (SFER):企業の財務・戦略的SWOT分析
    Salvatore Ferragamo SpA (SFER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Hornbeck Offshore Services, Inc. (HOS)-石油・ガス分野:企業M&A・提携分析
    Summary Hornbeck Offshore Services, Inc. (HOS) is a provider of marine services. The company offers marine transportation, subsea installation and accommodation support services to exploration and production, oilfield service, offshore construction and the US military customers. It supplies vessels, …
  • Femasys Inc:医療機器:M&Aディール及び事業提携情報
    Summary Femasys Inc (Femasys) is a medical device company that develops and manufactures medical device solutions for women’s healthcare. The company offers non-surgical female sterilization devices, and devices for the diagnosis of infertility, and cervical cancer diagnosis. Its products include fe …
  • Chevron Corporation (CVX)-エネルギー分野:企業M&A・提携分析
    Summary Chevron Corporation (Chevron) is an integrated oil and gas company. It operates in the oil and gas value chain from exploration and production, storage and pipeline transportation to refining, marketing and distribution of oil and gas products. Chevron explores for produces and transports cr …
  • Fingrid Oyj:発電所・企業SWOT分析
    Fingrid Oyj - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (execut …
  • ZoomMed Inc (ZMD)-医療機器分野:企業M&A・提携分析
    Summary ZoomMed Inc (ZoomMed) is a technical service provider that offers web solutions for medical sectors. The company’s product includes ZoomMed Network, ZRx Prescriber, PraxisLab, and EvPsych. It builds and operates a clinical information exchange platform between physicians and specialists, pat …
  • Neovasc Inc (NVCN)-医療機器分野:企業M&A・提携分析
    Summary Neovasc Inc (Neovasc) is a medical device company that develops, manufactures and sells products for cardiovascular disease. The company offers products such as tiara, reducer and tissue products. Its tiara is a novel transcatheter device that is designed for treating mitral regurgitation, a …
  • Cosmo Bio Co Ltd (3386):企業の財務・戦略的SWOT分析
    Summary Cosmo Bio Co Ltd (Cosmo Bio) operates as a medical device company that offers markets research reagents and research instruments. The company’s product categories include antibodies, assay and detection, cells and cell culture, bioactive substances, protein engineering, separation and purifi …
  • Syros Pharmaceuticals Inc (SYRS):製薬・医療:M&Aディール及び事業提携情報
    Summary Syros Pharmaceuticals Inc (Syros) is a biopharmaceutical company that develops medicines for the treatment of cancer, immune-mediated diseases, and other diseases. The company’s pipeline products under clinical trials include SY-1425, an oral, potent and selective RARa agonist that is used t …
  • Kuwait Food Company (Americana) K.S.C.P. (FOOD):企業の財務・戦略的SWOT分析
    Kuwait Food Company (Americana) K.S.C.P. (FOOD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …
  • San Leon Energy Plc (SLE):企業の財務・戦略的SWOT分析
    Summary San Leon Energy Plc (San Leon) is an oil and gas exploration and production company. It is engaged in acquiring, exploring and developing conventional and shale oil and gas assets across Europe and North Africa. The company holds interests in Durresi Block located in offshore Albania and inc …
  • Genomic Health Inc (GHDX)-医療機器分野:企業M&A・提携分析
    Summary Genomic Health Inc (Genomic Health) is a provider of genomic-based diagnostic tests and clinical laboratory services for the diagnosis of cancer. The company’s commercial product portfolio comprises Onco type DX breast cancer test, Onco type DX colon cancer test, Onco type DX prostate cancer …
  • Chr. Hansen Holding AS (CHR):企業の財務・戦略的SWOT分析
    Chr. Hansen Holding AS (CHR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • JSR Corp (4185):製薬・医療:M&Aディール及び事業提携情報
    Summary JSR Corp (JSR), formerly Japan Synthetic Rubber Co Ltd is a chemical manufacturing company. It produces a synthetic rubbers, emulsions and plastics. The company, along with its subsidiaries, provides general-purpose synthetic rubbers, special purpose synthetic rubbers, thermoplastic elastome …
  • InnaVirVax SA-製薬・医療分野:企業M&A・提携分析
    Summary InnaVirVax SA (InnaVirVax) is a biopharmaceutical company which discovers and develops products for the treatment of HIV/AIDS infection pathologically and novel cancer therapies. The company's pipeline product portfolio comprise DIAG-3S, an AIDS prognostic test; VAC-3S, an HIV AIDs therapeut …
  • Almarai Company:企業の戦略・SWOT・財務情報
    Almarai Company - Strategy, SWOT and Corporate Finance Report Summary Almarai Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Oryx Petroleum Corp Ltd (OXC):石油・ガス:M&Aディール及び事業提携情報
    Summary Oryx Petroleum Corp Ltd (Oryx Petroleum), a subsidiary of The Addax and Oryx Group Ltd, is an upstream company that explores oil and gas. The company explores, develops and produces natural resources. It holds interests in petroleum license areas in Africa and the Middle East. Oryx Petroleum …
  • Valero Energy Corporation (VLO)-石油・ガス分野:企業M&A・提携分析
    Summary Valero Energy Corporation (Valero) is a manufacturer and marketer of transportation fuels, petrochemical products and power. The company’s assets include petroleum refineries, ethanol plants, a wind farm and renewable diesel production from a joint venture. Its refineries produce gasoline, d …
  • Credit Suisse (UK) Private Banking:企業の戦略・SWOT・財務情報
    Credit Suisse (UK) Private Banking - Strategy, SWOT and Corporate Finance Report Summary Credit Suisse (UK) Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆